[Octreotide and a serotonin-secreting glomus tumor].
Glomus tumors arise in the chemical receptors of vessels in the tympanic and jugular regions. Clinical signs depend on location, the structures invaded and a tumor's ability to secrete active amines and peptides. A 44-year-old woman was scheduled for excision of a serotonin-secreting tympanic glomus tumor. Urinary excretion of 5-hydroxyindolacetic acid (5-HIA) in urine over the previous 24 hours was 80 mg (normal < 10 mg). The patient received oral diazepam, ranitidine, intravenous diphenhydramine and subcutaneous octreotide (150 micrograms). Anesthesia was induced with propofol, alfentanil and vecuronium. The tumor produced an episode of bronchospasm and cutaneous rubor during surgical manipulation of the tumor. Airway pressure increased to 42 cmH2O and SpO2 decreased to 89%. Hypotension and bradycardia appeared. Once it was suspected that the symptoms stemmed from tumoral secretion of active substances, 20 micrograms of intravenous octreotide was administered. The bronchospasm decreased and hemodynamic changes were resolved in three minutes, with no recurrence of symptoms. The patient received 100 micrograms of octreotide subcutaneously every 8 hours throughout the 72 postoperative hours. Urinary excretion of 5-HIA was 12 mg on the fifth day and the patient was released without having experienced complications. Appropriate preoperative preparation is important in patients with such tumors, as are early detection of respiratory and hemodynamic changes that may occur during surgery and correct perioperative treatment. Octreotide, a longer-lasting somatostatin analogue, has facilitated the handling of such cases.
García Galán
F
F
Servicio de Anestesiología y Reanimación, Hospital del SAS de Jerez de la Frontera, Cádiz.
Hernández Gudino
S
S
Estrada Fernández
J
J
García-Baquero
A
A
D000328:Adult; D001919:Bradycardia / Q000188:drug therapy* / Q000209:etiology; D001986:Bronchial Spasm / Q000188:drug therapy* / Q000209:etiology; D004890:Erythema / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005925:Glomus Jugulare Tumor / Q000150:complications / Q000378:metabolism* / Q000601:surgery / Q000652:urine; D006728:Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D007022:Hypotension / Q000188:drug therapy* / Q000209:etiology; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D007431:Intraoperative Complications / Q000188:drug therapy*; D016343:Monitoring, Intraoperative; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D011182:Postoperative Care; D011229:Preanesthetic Medication; D011300:Preoperative Care; D012701:Serotonin / Q000378:metabolism*
D006728:Hormones; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D015282:Octreotide
Octreótido y tumor glómico secretor de serotonina.